Lawrence O. Klein
2021
In 2021, Lawrence O. Klein earned a total compensation of $6M as Chief Operating Officer at CRISPR Therapeutics AG, a 63% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $273,375 |
---|---|
Option Awards | $3,618,965 |
Salary | $450,000 |
Stock Awards | $1,606,560 |
Other | $11,600 |
Total | $5,960,500 |
Klein received $3.6M in option awards, accounting for 61% of the total pay in 2021.
Klein also received $273.4K in non-equity incentive plan, $450K in salary, $1.6M in stock awards and $11.6K in other compensation.
Rankings
In 2021, Lawrence O. Klein's compensation ranked 2,124th out of 12,415 executives tracked by ExecPay. In other words, Klein earned more than 82.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,124 | 83rd |
Manufacturing | 821 | 85th |
Chemicals And Allied Products | 315 | 87th |
Drugs | 273 | 87th |
Biological Products, Except Diagnostic Substances | 84 | 81st |
Klein's colleagues
We found five more compensation records of executives who worked with Lawrence O. Klein at CRISPR Therapeutics AG in 2021.
2021
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
2021
Brendan Smith
CRISPR Therapeutics AG
Chief Financial Officer
2021
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
2021
James Kasinger
CRISPR Therapeutics AG
General Counsel
2021
Michael Tomsicek
CRISPR Therapeutics AG